CommercialPrior AuthMedium impact
08.02.18a, Elranatamab-bcmm (Elrexfio®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 4, 2026
We identified it
Jun 19, 2026
Summary
This policy update covers Elranatamab-bcmm (Elrexfio®), a specialty oncology medication, with changes to medical necessity criteria, coding guidelines, and general informational updates. The policy affects pharmacy benefit coverage and billing requirements for this cancer treatment drug.
Action Required
By May 4, 2026: Review updated medical necessity criteria for Elranatamab-bcmm (Elrexfio®) prior authorization requirements. Oncology providers and billing team must ensure documentation meets new criteria before submitting claims. Update prior authorization workflow for this specialty cancer medication to prevent claim denials.